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Low vegetable fiber intake and low urine volume are additional risk
factors for decreased urinary citrate in idiopathic calcium nephrolithiasis.
B. Hess, R. Michel, R. Takkinen, D. Ackermann, Ph. Jaeger, Med.
Universitatspoliklinik und Urologische Universitätsklinik, Inseispital
Bern, Switzerland. Risk factors for low urinary citrate (CIT) excretion
were assessed in 34 male recurrent calcium renal stone formers (RCSF)
without overt distal renal tubular acidosis (dRTA), who collected two
24-hr urines while on a free-choice diet. Additionally, RCSF as well as
14 healthy male controls (C) were studied both before and after 3 days
on NH4CI (I mEq/kg body wt per day, 3 doses, 20 mm before meals).
Net gastrointestinal alkali absorption (GI-ALKALI, normal> 15 mEq/
day) was calculated from 24-hour urine values as previously described
by Oh; intake of vegetable fibers (FIBERS, normal> 15 g/day), a main
source of alkali, was calculated from diet protocols of RCSF. LOW-CIT
was defined as U11 x V between 320 and 399 mg/day (1.70 to 2.11
mmol/day), and true hypocitraturia (HYPO-CIT) as U x V < 320
mg/day (< 1.70 mmol/day). Low urine volume (VOL) was defined as
24-hr urine VOL < 1200 ml. Values are means SEM. Among RCSF,
we found 23 with NORMO-CIT, 6 with LOW-CIT, and 5 with HYPO-
CIT. U1 x V positively correlated with GI-ALKALI (r = 0.47, P =
0.006), FIBERS (r = 0.46, P = 0.009), VOL (r = 0.44, P = 0.009) and
Uca X V (r = 0.57, P = 0.0004). After NH4CI, C never had SBIC < 20.5
mmol/liter or U> 5.32 on a nomogram of UPH vs. S; 16 out of 34
RCSF (47%), however, fell off this nomogram, indicating incomplete
dRTA. The latter occurred in 10 out of 11 RCSF with LOW-/HYPO-
CIT, compared with 6 out of 23 RCSF with NORMO-CIT (P = 0.0004,
chi-square). GI-ALKALI was lower in HYPO-CIT (14 4 mEq/day)
than in LOW- (39 7 mEq/d, P < 0.025) and in NORMO-CIT (36 5
mEq/day, P < 0.05). In the LOW-/HYPO-CIT group, FIBERS were
11.9 1.6 g/day, lower than in NORMO-CIT (18.3 1.8 g/day, P =
0.037). Low VOL tended to be more frequently associated with
LOW-/HYPO-CIT. Two or more risk factors simultaneously occurred
in only 4 out of 23 RCSF with NORMO-CIT, but in 8 out 11 with
LOW-/HYPO-CIT (P = 0.002). In summary, incomplete dRTA is the
most prevalent risk factor for LOW-/HYPO-CIT in RCSF; additionally,
decreases in vegetable fiber intake and urine volume emerge from this
study as two new risk factors for low urinary CIT.
Apparent autosomal dominant inheritance in primary hyperoxaluria
type I. B. Hoppe, C.J. Danpure, C. Braegger, A. Colombi, G. Schu-
biger, E. Leumann, Universitãts-Kinderklinik Zurich, Kantonsspital
and Kinderspital Luzern, Switzerland, and Clinical Research Centre,
Harrow, United Kingdom. Primary hyperoxaluria type I (PH I) is
known as an autosomal recessive disease, with elevated urinary excre-
tions of oxalate and glycolate due to deficiency of liver-specific perox-
isomal alanine:glyoxylate aminotransferase (AGT). We have observed
severe PH I in a male infant whose mother has PH. Her brother had
died of generalized oxalosis 4 years after unsuccessful renal transplan-
tation. Further family screening was negative. The infant presented
with renal failure (serum creatinine 155 mol/liter, normal < 40) at 8
months of age; oxalic acid excretion was 1.19 to 1.73 mmol/24 hr/i .73
m2 (normal < 0.5). Glycolic and L-glyceric acid excretion were normal
in both mother and infant. Liver AGT catalytic-activity was 18.2% in
the infant and 15.9% in the mother, and only 10% of the activity was
peroxisomal. DNA analysis showed that the infant is homozygous for
the G630-A mutation that is classically associated with peroxisome to
mitochondrial AGT-mistargeting, while both parents are heterozygous.
The infant and father are homozygous for the C154-T polymorphism,
which contributes to the AGT targeting defect when present with the
G630-A mutation; the mother is heterozygous. PH I in infant and
mother is partly pyridoxine sensitive. Although both have the same
phenotype (despite different clinical manifestations), they appear to
have a distinct genotype. As the mother is only heterozygous for the
Cl54-T/G630-A mutant allele, her presumably normal allele possesses a
different mutation which also leads to an expression failure or results in
mistargeting. So far it appears that the vertical transmission of PH I in
this family is pseudo-dominant. Screening of PH in family members of
affected patients is necessary.
Catch-up growth in children with renal tubular acidosis. M.-S. Ghuy-
sen. J.-P. Guignard, Service de pédiatrie, CHUV, Lausanne, Switzer-
land. Failure to thrive is commonly associated with the presence of
chronic metabolic acidosis. Renal tubular acidosis (RTA) is a common
cause of metabolic acidosis in children. It may be the consequence of
proximal bicarbonate wasting (proximal RTA) or deficient distal net
acid excretion (distal RTA). The aim of this study was to evaluate the
effect of mild RTA on growth, and the response to alkali therapy.
Twenty-four children (mean age 21 months; range 2 months to 13 years)
with RTA were studied by current acidification tests, including the
response to an acute acid load, the determination of the bicarbonate
renal threshold, and the urine minus blood PCO2 during alkaline
diuresis. They were subsequently divided into two groups according to
the tubular site of the acidification defect, and followed for a mean
duration of 26 months (range 6 to 81 months). Treatment with sodium
bicarbonate or sodium citrate was adjusted every I to 3 months so as to
maintain the actual plasma bicarbonate and base excess in the normal
range. The presenting symptoms were failure to thrive (96%), anorexia
(54%), vomiting (29%), polyuria (8%) and rickets (4%). Group A(proximal RTA) included 19 children and group B (distal RTA) 5
children. Mean plasma bicarbonate at the time of diagnosis was 17.5
5 mmollliter in group A and 17.0 4 mmol/liter in group B. Urine
calcium excretion was normal in group A (0.48 0.38 mol/mol
creatinine) and moderately elevated in group B (1.98 1.22). To
achieve normal plasma bicarbonate levels, group A required 4.2 2.8
mmol/kg per day and group B 2.1 0.2 mmol/kg per day of sodium
bicarbonate. Height and weight were measured at 3 months intervals.
Height was expressed in standard deviation score (SDS) for each child
and growth rate over time measured in terms of changes in SDS for
height. The following mean results for both groups were: —1.48 SDS at
diagnosis; —1.12 SDS at 6 months after initiating treatment; —0.88 SDS
after 1 year; —0.79 SDS after 2 years; —0.53 SDS after 3 years and
—0.06 SDS after 4 years. We conclude: (1) that appropriate alkali
therapy in children with RTA results in catch-up growth and (2) that the
presence of occult RTA should be looked for whenever failure to thrive
is present in a child.
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Transforming growth factor-fl! stimulates glomerular mesangial cell
synthesis of the 72 kDa type IV collagenase. H.P. Marti, L. Lee, M.
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Kashgarian, and D.H. Lovett, Department of Medicine, San Francisco
VAMC-University of California at San Francisco, San Francisco,
California, and Department of Pathology, Yale University, New Ha-
ven, Connecticut, USA. Transforming growth factor-$l (TGF-pl) is
generally considered to exert positive effects on the accumulation of
extracellular matrices. These occur as the net result of enhanced matrix
protein synthesis, diminished matrix metalloproteinase (MMP) synthe-
sis and augmented production of specific inhibitors, including the tissue
inhibitor of metalloproteinases (TIMP-l). Given that glomerular
TGF-/31 synthesis is induced by inflammation, the effects of this
cytokine on synthesis of the 72 kDa type IV collagenase and TIMP-l by
cultured human mesangial cells (HMC) were evaluated. Concentrations
of TGF-131 of 5 ng/ml and above specifically stimulated the synthesis of
the 72 kDa type IV collagenase. This effect was independent of the
stimulatory effect of TGF-pl on TIMP-l synthesis, which was maximal
in a lower concentration range (0.1 to 1 ng/ml). Most significantly, the
net effect at the higher concentrations of TGF-pl was an excess of
enzyme over the TIMP-1 inhibitor. Northern blot analysis of TGF-13l
stimulated HMC demonstrated a specific increase in the abundance of
the 3.1 kb mRNA transcript encoding the 72-kDa type IV collagenase,
presumably mediated by a direct stimulation of 72-kDa type IV colla-
genase mRNA transcription observed as early as three hours following
exposure to TGF-131. These studies were extended to an analysis of the
expression of TGF-/31 and 72 kDa type IV collagenase mRNA's in
normal and nephritic rats. In normal animals, basal TGF-pl and 72 kDa
type IV collagenase mRNA expression was observed in a strictly
mesangial distribution. Following induction of acute immune complex-
mediated glomerulonephritis, there was a major increase in TGF-pl and
72 kDa type IV collagenase mRNA expression which was strictly
limited to the expanded, hypercellular mesangial compartment. En-
hanced synthesis of the mesangial 72 kDa type IV collagenase in
response to TGF-/31 released during glomerular inflammatory processes
could have an important role in the extensive glomerular matrix
remodeling which accompanies these disorders.
Effect of antl-TNF antibody on mesangial cell proliferation. N. Bena-
dor, G. Grau, C. Ruef, E. Girardin, Département de Pédiatrie, Hôpital
Cantonal Universitaire, Genève, Switzerland. Mesangial cells (MC) are
one cellular source of tumor necrosis factor alpha (TNFa) within the
kidney as shown by experimental stimulation with endotoxin. TNFa
increases MC synthesis of PGE2 which down-regulates MC prolifera-
tion. More recently, TNFa was shown to mediate PGE2 release and
growth inhibition of glomerular MC induced by activated T-lympho-
cytes. The participation of TNFa as an autocrine factor in the control of
MC proliferation is unknown. This role was evaluated in vitro by the
addition of anti-TNF antibody to MC. Rat MC from primary culture
were cultured in serum-free medium, with 0.5 and 10% fetal calf serum
(FCS). For each condition rabbit anti-mouse polyclonal TNF antibody
was added at concentrations of 2, 4, 20 pg/ml. Cell proliferation was
studied by 3H-thymidine incorporation. Results were the following:
Antibody
MC proliferation index
g/ml Serum free FCS 0.5% FCS 10%
2 1.7 0.3 1.6 0.2 0.9 0.1
4 2.4 0.4 1.9 0.3 1.0 0.1
20 3.4 0.4 3,0 0.7 1.1 0.1
Anti-TNF antibody induced a dose dependent increase of cell prolifer-
ation when the cells were quiescent in serum-free or in 0.5% FCS (P <
0.001). No effect was found when the cells were stimulated with 10%
FCS (P = 0.464). Indomethacin alone at concentrations of 1 and 10
ig/ml had no effect on mesangial cell proliferation in serum free and
0.5% FCS (P = 0.391 and 0.719). When added with anti-TNF antibody,
indomethacin did not modify the proliferative response (P = 0.100).
Anti-TNF antibody promoted MC growth by blocking endogenous
TNFa. The mechanism of action was not mediated by prostaglandin E2.
This indicates that endogenous TNFa participates in the control of
mesangial cell proliferation when they are in a resting state.
E. coIl-derived lipopolysaccharide (LI'S) induces bovine glomerular
endothellal cell (GEC) injury and stimulates glomerular mesanglal cell
(GMC) contraction in vitro. V.A. Briner, Cli. von Grunigen, Medizini-
sche Universit/.usklinik, Inseispital, Bern, Switzerland. Acute renal
failure (ARF) is a characteristic finding in septicemia. Results of in vivo
and in vitro studies demonstrate increased glomerular constriction and
decreased glomerular filtration rate (GFR). These effects may occur
even in the absence of critically reduced blood pressure. The present
study was designed to investigate direct LPS (E. coli) effects in cultured
glomerular cells which are known to modulate GFR, namely GEC and
GMC. LPS (1 ng/ml) exposure of GEC did not affect cellular prolifer-
ation, however, it tended to elongate the cellular shape. A dose of 10 ng
to I g/ml LPS produced GEC detachment. The toxic effects of LPS
were reduced but not prevented in quiescent GEC. Inhibition of protein
synthesis by cycloheximide (100 ng/ml) also reduced cell proliferation,
however, and enhanced LPS-induced injury. In contrast, incubation of
GMC with LPS (0.1 ng to 10 g/ml) had no effect on morphology (light
microscopy) and cells did not detach. LPS (0.1 ng to 1 p.g/ml) also did
not inhibit GMC proliferation. Incubation of GMC for 10 mm with LPS
(5 jg/ml) stimulated GMC contraction as measured by digital imaging
analysis. In GEC LPS (100 ng/ml for 4 to 7 mm) exposure activated
protein kinase C (PKC) (control: cytosolic 85 8%, membrane 15
2.2%; LPS: cytosolic 69 2.3%,membrane fraction 31 2%; P <0.01)
and increased cyclic AMP (cAMP) production (LPS 45.4 0.9 pg/mg
protein; control 37.6 I pg/mg protein; P < 0.05). Pre- and co-
incubation of GEC with LPS and phorbol ester down-regulated and
activated PKC, respectively, but stimulation of cAMP production by
forskolin, however, did not mimic LPS effects. In GEC a very low dose
(10 ng/ml) of LPS inhibits cell growth and has cytotoxic effects. LPS
effects are not mediated by activation of PKC and PKA and is not
prevented by inhibiting protein synthesis. A concentration of LPS
which induces damage to GEC neither affects GMC growth nor cellular
detachment. However, LPS exposure of GMC induces contraction. In
conclusion, in septicemia LPS-induced GEC injury and GMC contrac-
tion may occur. Thus, the glomerulus contraction-dilation state may be
balanced insufficiently and lead to impairment of GFR and contribute to
ARF in endotoxemia.
Endotoxin increases glomerular hemodynamic resistance by sequential
activation of thromboxane, PAF and endothelin.1. H.A. Bock, V. Muller,
M. Hermle, F.P. Brunner, G. Thiel, Abteilung Nephrologie, Kantons-
spital Base!, Switzerland. To elucidate the mechanisms responsible for
the endotoxin-induced fall of GFR, we studied the hemodynamic
response of single glomeruli to in vitro endotoxin perfusion. Single
microdissected rabbit glomeruli with intact Bowman's capsule were
cannulated and perfused in vitro with electrolyte solution via concentric
micropipettes, which were advanced to the intraglomerular capillary
branching point via the afferent arteriole. Pressure at this point was kept
at 40 2 mm Hg. Glomerular (= intraglomerular plus efferent)
resistance and volume (videomicroscopy) were determined in 20 minute
periods (2 x 20' control —* x 20' experimental). Pseudomonas
endotoxin, the TxA2 agonist U-46619 and endothelin-l were perfused
alone or with receptor antagonists for TxA2/PGH2 [SQ-295481, PAF
[BN-52021J and endothelin-l [BQ123) (—* Table). The effects of U-46619
and endothelin-l were also each blocked by their respective antagonist.
AResistance A Volume N
Endotoxin 6 tg/ml +50 12%U —8 2%0 8
End + SQ-29548 106 M +12 11% 0 1% 7
End + BN-52021 l0 as +5 7% —l 1% 7
End + BQ123 106 M +8 7% 0 1% 5
U-46619 106 as +90 35%O —6 l%O 6
U-46619 + BN-52021 +14 5% +1 1% 5
U-46619 + BQ123 +6 7% +2 1% 4
Endothelin lO M +164 69W —4 2% 5
Endothelin + BN-52021 +246 112%" —4 2% 4
Data are mean SEM. °P < 0.01, b < 0.05
In conclusion, endotoxin increases resistance at an intraglomerular site,
since afferent arteriolar resistance is eliminated by design and efferent
constriction would increase glomerular volume. Since both the PAF
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and the endothelin antagonist block endotoxin and U-46619, but only
BQ123 blocks endothelin, endotoxin appears to activate a serial cas-
cade which includes (in this order) TxA2, PAF and endothelin. This is
consistent with the concept that a PAF- and endothelin-mediated
mesangial contraction significantly contribute to the GFR fall in endo-
toxinemia.
Serum calcitriol (1,25-D) positively correlates with renal mass in
recurrent idiopathic calcium renal stone formers (RCSF): Role of protein
intake. B. Hess, L. Villiger, D. Ackermann, Ph. Jaeger, Med. Univer-
sitdtspoliklinik und Urologische Universitdtsklinik, Inseispital Bern,
Switzerland. To see whether 1 ,25-D levels depend on actual renal mass,
we studied 20 male RCSF on a free-choice diet (two 24-hr urines), 11
with hypercalciuria (HCSF, Ua x V > 7.5 mmol/day), and 9 with
normocalciuria (NCSF). Renal mass was assessed by the sum of surface
areas of both kidneys (AREAR+L, cm2), directly measured on plain
films of the abdomen (KUB) by a computer-assisted sonic stylus
(PICA). U, x V (mean of two 24-hr urines) was taken as a marker of
protein intake; 1 ,25-D was measured immunoradiometrically. RCSF as
well as 13 age-matched healthy controls (C) also underwent an oral
calcium load (OCL, 1 g of calcium-lactate-gluconate/calcium carbonate)
added to a standard breakfast after 13 hours of overnight fasting. Blood
and urine samples were collected hourly over the 6 hours following
OCL. Values are means SEM. Taking all RCSF together, there were
positive correlations between 1,25-D and both Ccrea (r = 0.472, P =
0.035) as well as AREAR+L (r = 0.513, P = 0.025). Also, Ccrea
positively correlated with U, x V (r = 0.511, P = 0.021) and with
AREAR+L (r = 0.474, P = 0.040). Ccrea (113.5 5.2 vs. 94.8 4.1
mI/min/! .73 m2, P = 0.009) as well as AREAR+L (159.1 4.7 vs. 143.5
6.5 cm2, P = 0.017) were higher in HCSF than in NCSF. Serum
l,25-D was 56.8 4.4 pg/mI in HCSF vs. 42.3 3.1 pg/mI in NCSF (P
= 0.019) and 50.6 5.1 pg/mI in C (NS vs. HCSF and NCSF). In fasting
urines as well as at all times after OCL, urinary Ca/Crea was higher in
HCSF than in NCSF and C; total urinary Ca output after 6 hours was
3.70 0.34 mmol in HCSF vs. 2.27 0.27 mmol in NCSF (P = 0.011)
and 2.50 0.20 mmol in C (P = 0.013). In conclusion, high protein
intake rises GFR, a phenomenon associated with increased renal mass.
The latter is accompanied by elevated levels of serum 1 ,25-D which
probably account for both the high calciuria after OCL and the
hypercalciuria encountered in HCSF.
Anticoagulation in patients treated by continuous veno-venous hemo-
filtration (CVVH): A retrospective study. P.- Y. Martin, P.M. Suter,
f-C. Chevrolet, H. Favre, Département de Médecine et Anesthésie,
Hôpital Cantonal Universitaire de Genéve, Genève, Switzerland. Two
hundred and fifty-five critically ill patients, mean SD age 58.2 16.3
have been treated by CVVH between 1986 and 1992. Blood was
circulated through hemofilters, either polyacrylonitrile (AN 69 Hospal)
or polyamide (FH 66 Gambro), using a blood pump and an air safety
system. Median duration of the treatment was 144 hours (range 4 to
1152 hours). There were no differences in requirement of heparin
between the 2 types of membrane: AN 69 vs. FH 66 mean SD, 393
LU/hr 106 vs. 374 lU/hr 35.3. 37 patients (14.5%) had no
anticoagulation (Group 1), 189 patients (74.1%) received 100 to 700
lU/hr of heparin (Group 2) and 29 patients (11.4%) received more than
700 lU/hr heparin (Group 3). There were no relationships between the
amount of heparin and the mean survival of the filters (Group 1 22.1
14.8 hr; Group 2 24.7 13.2 hr; Group 3 23 9.6 hr). The only routine
coagulation parameters which differs significantly between Group 1,
Group 2 and Group 3 was initial platelet counts (Group 1 42,000/id;
Group 2 l41,730/.d; Group 3 2ll,000/pi; ANOVA P = 0.001). Under
CVVH, platelet count fell significantly from 211 ,000/pi to l22,000/pi in
Group 3 and from l4l,730/d to ll3,735/t1 in Group 2, in contrast to
Group I where they remained stable. Mortality was higher in Group 3
(69%) and Group 1(73%) than in Group 2 (51.4%). The global death rate
was 56.4%. Conclusions are: (a) most patients had an adequate antico-
agulation with low dose heparin; (b) platelet count is the best predictor
of the feasibility of CVVH without anticoagulation in patients with an
hemorrhagic risk; (c) CVVH significantly decreases platelet counts in
patients from Group 2 and 3, but has no effects in patients who started
with coagulation abnormalities.
Hyperkalemia after hemofiltratlon. U. Binswanger, A. Knoflach, J.
Bleisch, J. Zaruba, H. Kubista, S. Jung, Nephrologische Abteilung,
Departement fur Innere Medizin, Universitatsspital Zurich, Switzer-
land. Initial hemofiltration followed by hemodialysis is an established
procedure for treatment of patients with excessive weight gain. Over-
weight is sometimes accompanied by hyperkalemia reflecting non-
compliance of patients. The purpose of this study was to investigate
electrolyte changes during hemofiltration/hemodialysis sessions. Dur-
ing hemofiltration for 30 to 60 mm and removal of 1.5 to 2.5 liters, serum
potassium rose in all patients tested from 6.09 0.74 to 6.52 0.83
mmol/liter (N = 7, P < 0.01, paired t-test; ISE, AVL). Sodium was not
changed: 143.8 2.8 to 142.9 3.1 mmol/liter (NS). Potassium
concentration before and after the capillary dialysis filter (F6, F8, F60
or F80) were unchanged; ultrafiltrate potassium closely reflected serum
concentrations. Extending such studies to less hyperkalemic patients(K 5.06 0.40 mmol/liter) with less overweight showed a slight
decrease of K during isolated hemofiltration. It is concluded that in a
group of hemodialysis patients exhibiting excessive weight gain and
hyperkalemia serum potassium increases further during hemofiltration
reaching values >6 mmollliter in 4/7, >7.5 mmol/liter in 2/7 studies.
Causes of intracorporal redistribution include /3-adrenergic blockade
(pharmacologic or by uremia) and a-adrenergic stimulation during
volume decrease. Deliberate use of hemofiltration before hemodialysis
should be reconsidered in view of the development of excessive
hyperkalemia.
Changes in the level of prothrombin fragments (F1.1.2) under anticoag-
ulation with heparin during hemodialysis. P.M. Ambühl, R. Wüthrich,
W. Korte, R. Krapf, Medizinische Klinik B, Kantonsspital, St. Gallen,
Switzerland. Prothrombin fragments (F12) are generated in an equimo-
lar ratio to thrombin and are considered to be accurate markers to
monitor and adjust anticoagulation with heparin. To investigate their
utility to guide heparin administration during hemodialysis (HD), we
investigated 29 patients with end-stage renal disease undergoing hemo-
dialysis and standard heparin treatment (bolus, followed by constant,
continuous i.v. infusion until 30 mm to completion of HD). The amount
of heparin required to prevent clotting of the filter without prolonged
bleeding after HD had been determined earlier and individually for each
patient based on clinical observation (the average bolus dose consisted
of 1 '600, the average dose per hour of 1 '200 IE heparin). PTT and F1
were measured before initiation of HD (0); 30 (1), 90 (2) and 120 (3) mm
into HD; at discontinuation of heparin 30 minutes before the end of HD
(4) and immediately after HD has been completed (5). The values for
PTT (mean SD) at time 0 were in the normal range for virtually all
patients (0, 37.2 6.9 seconds; normal range 28 to 40 seconds). Under
treatment PT!' was prolonged as anticipated up to approximately
2.5-fold during the first 90 minutes, showing a broad interindividual
variation (1, 83 49 seconds; 2, 83 52 seconds) and declined
constantly towards the end of treatment (3, 65 42 seconds; 4, 61 24
seconds; 5, 49 17 seconds). In contrast F12 were markedly elevated
above the normal range already before initiation of treatment (0, 2.8
1.25 nmol/liter; normal range 0.40 to 1.10 nmol/liter). Surprisingly, they
remained virtually unchanged throughout HD (1, 3.3 1.5 nmol/liter; 2,
3.5 1.3 nmol/liter; 3, 3.0 0.9 nmol/liter; 4, 3.3 1.3 nmollliter; 5,
3.66 1.3 nmol/liter). To quantitate the activation of the coagulation
system due to contact with the extracorporeal device, we heparinized
without HD a small subgroup (N = 4) of the patients. Interestingly, the
level of F1÷2 showed the same course as during hepannization with HD.
In conclusion, F12 are elevated in hemodialysis patients, probably
reflecting permanently activated coagulation resulting from vascular
alterations including dialysis shunts. Moreover, a clinically adequate
anticoagulation under HD does not affect the level of F1 +2' neither does
heparin alone. The reason for this remains to be identified (pharmaco-
kinetics, dosage, individual differences), but probably makes F1÷2
unsuitable for monitoring and dosage of heparin under HD.
Acetate (A) vs. bicarbonate (B) buffered hemodialysis: Extraction of
urea. A. Knoflach, U. Binswanger, Nephrologische Abteilung, Depar-
tement für Innere Medizin, Universitätsspital Zurich, Zurich, Switzer-
land. Urea extraction during paired acetate (A) and bicarbonate (B)
buffered hemodialysis (38 mEq/liter) was found to be different: dialysate
urea averaged 472.3 63.9 (A) vs. 411.5 87.2 (B) mmol per treatment
(P < 0.05). Hemodynamic monitoring by impedance techniques re-
vealed tendencies towards lower cardiac output and lower peripheral
vascular resistance during A. Blood recirculation (access plus systemic)
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at the end of dialysis amounted to 5.68 3.0 (A) vs. 5.21 1.0% (B)(P = NS). Urea generation during A vs. B as obtained by urea kinetic
modeling according to Depner was 7.29 1.8 mg/mm (A) vs. 5.85 1.5
mg/mm (B) (P < 0.05). Normalized protein catabolic rate was not
different: 1.06 0.2 (A) vs. 1.01 0.3 g/kg body weight (B). It is
concluded that increased urea generation during A buffered hemodial-
ysis is associated with a larger urea extraction. Better clearing of
"opened" vascular compartments seems less important in view of
comparable recirculation data and minor changes in hemodynamic
indices.
Influence of dialyzer clearance (K) measurement accuracy on hemodi-
alysis (HD) based on K t/v. C. Zehnder, A. Blumberg, Nephrologie,
KantonsspitalAarau, Aarau, Switzerland. K tiv has been used to judge
the adequacy of HD. The aim of this study was to compare different
forms of K measurements and their influence on K t/v. Sixteen patients,
aged 55.3 13.3 years on high flux HD (7 acrylonitrile 2.0, 9
polysulphone 1.25 m2 filters) for 4.03 0.29 hours were studied with Qb
250 (Qd 497 15) and with Qb 350 (Qd 495 17) mI/mm. K urea (u) was
measured by the arterio-venous (av) blood sampling technique (KbU) at
15 mm, corrected by access recirculation (Kb) and compared with K
as determined by dialysate collection (KdU). K creatinine (cr) was used
as control. Volume (v) was calculated based on patient's height and
weight. Results (mean SD):
Qb 250 mI/mm Qb 350 mI/mm
Kb 203.0 93° 243.6
Kb,.,
KdU
KbUtIV
KdU t/v
191.2 11.5°
169.0 13.3°
1.33±0.17°
1.11 l.13a
227.7 155ab
196.5 173ab
1.58±0.l9°'
1.27 015ab
a Kb Kd, P < 0.0005
"Qb 250 vs. Qb 350, P < 0.0005
The difference between KbU and KdU increased from 16.7 5.1 (Qb 250)
to 19.4 5.9 (Qb 350) % (P < 0.05). KbU correlated with and Kd,,
with Kd. (r = 0.83 and 0.90, respectively, P < 0.001). We conclude that
dialyzer clearances based on av differences in blood overestimate the
real clearances (and therefore K t/v) as measured by dialysate collec-
tion. This overestimation increases with rising Qb.
Distribution of renal diseases in 660 renal graft recipients over the last
24 years. A. Klein, F.P. Brunner, G. Thiel, Abteilung Nephrologie,
Departement Innere Medizin, University of Base!, Base!, Switzerland.
We have analyzed the distribution of renal disease in 660 renal
transplant recipients receiving 756 renal grafts from 1967 till 1991.
During this analysis we have given special attention to three questions:
(1) etiology of renal disease leading to renal replacement therapy; (2)
has the age of patients reaching end-stage analgesic nephropathy
changed over the years? We expected a growing age since the consump-
tion of phenacetin was stopped after 1982, adding no younger addicts to
the old customers. (3) Has the time changed between the first symptoms
of diabetes mellitus and end-stage diabetic nephropathy? Because of
more potent antihypertensive drugs, more sophisticated insulin prod-
ucts and an improved knowledge in handling diabetes mellitus, we
expected an increasing delay between onset and end-stage. The 660
patients were divided in four time periods: 1967—73, 74-79, 80—85 and
86—91, when the first graft was given. The statistical analysis for
changing pattern was calculated with Fischer exact test for 2 x 4 tables.
The following diseases were responsible for irreversible end-stage renal
failure: 31% glomerulonephritis, 18% analgesic nephropathy, 12% poly-
cystic kidney disease, 8% chronic pyelonephritis, 8% diabetes, 6% rare
kidney diseases, 3% nephrosclerosis and 7% shrunken kidneys from
unknown origin. The frequency of analgesic nephropathy has decreased
(P < 0.05) and the age of patients reaching end stage analgesic
nephropathy has increased (P < 0.001). More patients with diabetic
nephropathy were transplanted (P < 0.05), but the interval between
onset of diabetes and endstage diabetic nephropathy remained un-
changed over all 4 time periods (median: 20 years, 22, 20.5 and 20.5
years). In conclusion: (I) Glomerulonephritis remains the major cause
for renal failure in our transplant recipients. (2) Classical analgesic
nephropathy is slowly disappearing. The legal measures taken 1982
were effective. (3) The time between onset diabetes and end-stage
diabetic nephropathy remains remarkably stable. Changes of treatment
in the years before (1955—1970) were of no obvious benefit for diabetic
renal disease.
Is analgesic nephropathy decreasing In Switzerland? J.G. Pannatier,
J.P. Wauters, Division de Néphrologie, CHUV, Lausanne, Switzer-
land. Several years ago, the incidence of analgesic nephropathy (AN)
observed in several European countries has usually led to restrictions
on the OTC sale of phenacetin containing analgesics; those measures
resulted in a progressive decrease of AN after a latency of five to ten
years. In Switzerland restriction on the sales was obtained only in 1981
when the incidence of AN among the patients starting dialysis
amounted to 28%. At that time the sale of all drugs containing
phenacetin was bound by prescription, and as a result phenacetin was
replaced by paracetamol in almost all available compounds. Due to
their similar renal elimination, the effectiveness of this approach was
questioned by most nephrologists. Therefore we retrospectively ana-
lyzed the incidence of AN among the 593 patients starting dialysis in our
unit between 1969 and December 1992. Before 1985, 54 patients out of
315 suffered from AN (17%), and since 1985 only 18 patients out of 278
suffered from AN (6.5%). The proportion of AN fell from the highest
incidence of 32% in 1981 to 2% in 1992. Simultaneously in Switzerland,
according to the EDTA Registry, the incidence of patients with AN fell
from 28% in 1981 to 12% in 1990. Despite the interference of other
factors (changing selection criteria for ESRF patients, difficulties in
diagnostic criteria, incomplete reporting to the EDTA Registry, etc.),
those data seem to indicate that the measures taken in 1981 have had a
beneficial effect in the incidence of AN leading to ESRF. The efficacy of
the replacement of phenacetin by paracetamol can probably be ex-
plained more through central nervous system than through renal
side-effects.
Acute effects of aspirin on renal function hi rabbits. L. Ballèvre, 0.
Grigoras, N. Davila, 1.-P. Guignard, Service de pédiatrie, CHUV,
Lausanne, Switzerland. In humans, severe impairment of glomerular
filtration rate (GFR) and renal blood flow (RBF) has been observed after
the use of non-steroidal anti-inflammatory agents. Inhibition of pros-
taglandins (PG) synthesis has been claimed to mediate the decrease in
GFR. The functional renal effects of aspirin (Aspegic5 40 mg/kg i.v.)
and the possible participation of the renin-angiotensin system in the
response to aspirin have been investigated in 20 anesthetized mechan-
ically ventilated rabbits. The animals were infused with a mannitol-
Ringer solution, at a rate of 1 mI/mm. Plasma electrolytes, proteins,
hematocrit and acid-base parameters were kept constant throughout the
experiment. In 12 animals weighing 2.477 0.106 kg, the experimental
protocol included a 20-mm control period (C) and four 20-mm periods (I
to IV) after aspirin administration. Body temperature, blood pH, P02
and PCO2 were maintained constant throughout the experiment. Blood
pressure (BP), urine output (V), GFR (inulin clearance), RBF (paraami-
nohippuric acid clearance), renal vascular resistance (RVR) and filtra-
tion fraction (FF) were assessed. Significant changes from period C to
period Ito IV were noted, the most important being in period I: GFR
(—22.4%), RBF (—16.3%), RVR (+19.5%), FF (—8.6%). The same
qualitative changes were measured during period II to IV. In a second
group of 8 animals weighing 2.540 0.161 kg, perindoprilat (20 ag/kg
i.v.), an angiotensin converting enzyme inhibitor was injected after the
administration of aspirin. The experimental protocol successively in-
cluded a 20-mm control period (C), a 40-mm period (perindoprilat
control) and four 20-mm periods (Ito IV) after aspirin administration.
The renal effects of aspirin were completely blunted by perindoprilat,
no significant change in GFR, RBF, RVR and FF being noted, when
comparing the aspirin periods I to IV to the perindoprilat control
period. It is concluded that: (1) aspirin, a PG synthesis inhibitor,
induces severe renal vasoconstriction in anesthetized rabbits; (2) an-
giotensin II plays an important role in this vasoconstriction; (3) the
aspirin-induced vasoconstriction can be prevented by the concomittant
administration of an angiotensin Il-converting enzyme inhibitor.
Osteocalcin is a useful marker for activity of renal bone disease during
hemodialysis. H. Gantenbein, J. Bleisch, P. Pei, U. Binswanger,
Nephrologische Abteilung und Institut für klinische Chemie, Universi-
tatsspital Zurich, Zurich, Switzerland. Osteocalcin is a non-collagenous
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bone matrix protein. Due to its bone specificity it is presumed to be a
biochemical marker for the assessment of bone diseases. We measured
osteocalcin, alkaline phosphatase, bone fraction of alkaline phos-
phatase, ionized calcium and parathyroid hormone (Nicholls intact
hormone assay) in 26 patients (age 45.7 years, range 45 to 75; time on
dialysis 1.9 years; range 0.1 to 11). A total of 116 measurements were
obtained during a period of three to 16 months. Patients with high serum
phosphorus were treated with a phosphate binder, usually calcium-
acetate or seldom with aluminium-hydroxide. Patients with PTH levels
higher than three times the upper limit of the normal range or low
ionized calcium were treated with I ,25-dihydroxycholecalciferol con-
tinuously 0.25 sg/day or 2 .&g/three times per week after dialysis. We
found a linear correlation of osteocalcin with PTH blood levels (r =
0.62, P < 0.001), whereas alkaline phosphatase and the specific bone
fraction of this enzyme did not show such a relationship. The scattered
distribution around the correlation line indicates that the PTH-induced
bone changes are modified by uremia related factors and/or therapeutic
measures. The physiological feedback relation between ionized calcium
and PTH was absent and not restored by therapeutic interventions. In
conclusion, osteocalcin combined with PTH measurements is useful for
detection of established and progressive renal bone disease.
Increase of bone mineral density (BMD) in calcitriol treated chronic
hemodialysis patients (HD pts). D. Kiss, K. Donauer. Dialysestation,
Medizinische Klinik, Kantonsspital Liestal, Liestal, Switzerland. To
assess the effect of calcitriol therapy on BMD, 24 chronic HD patients
(pts) were investigated over a two year period. All pts were treated with
a phosphate binder and 12 pts were treated with calcitriol (0.25 to 0.5
pg/day) orally (Group I). The 12 pts without calcitriol served as controls
(Group II). The biochemical bone markers [i-PTH, calcium (Sea),
phosphate (Se), osteocalcin (OC) and alkaline phosphatase (AP)] were
determined every 2 months and therapy was adjusted so that S, was
below 1.80 mmol/liter, Sa above 2.20 mmollliter and i-PTH below 250
pg/mi. In case of hypercalcemia (>2.60 mmollliter) the Ca concentra-
tion of the dialysate was lowered. Both at the beginning and at the end
of the investigation, BMD of the lumbar spine was measured by
quantitative computer tomography (QCT). The results are summarized
in the Table. Data are expressed as mean SD.
i BMD
N mg/cc
i-PTH
pg/ml
Group I 12 +11 5.5 117 24
Group!! 12 —14 7.5 129 34
P <0.005 NS
oc
ng/ml
sCa sP AP
U/litermmol/liter
44 16 2.52 0.11 1.81 0.12 105 11
36 19 2.54 0.08 1.75 0.11 97 9
NS NS NS NS
Due to insufficient suppression of PTH activity (>200 pg/mI) two pts
had a decrease of BMD in Group!. Due to prior parathyroidectomy two
pts had an increase of BMD in Group II. Additionally there was a
significantly (P < 0.05) negative correlation between the change of
BMD and PTH activity (r = 0.72). As long as PTH secretion is
suppressed sufficiently (<180 pg/mI), calcitriol therapy leads to an
increase of BMD in chronic HD pts. In cases of successful parathy-
roidectomy BMD increases without calcitriol therapy. Without cal-
citriol therapy BMD decreases and is more pronounced in pts with high
PTH activity (>100 pg/mI). In addition to biochemical bone markers,
regular measurement of BMD is necessary when making pharmacolog-
ical or surgical therapy decisions in chronic HD pts.
Which parameters of iron status are reliable during hemodialysis
treatment? J. Rosman, G. Vogel, E. Descombes, P. de Werra, G.
Fellay, J.P. Wauters, Division de Néphrologie, CHUV, Lausanne,
Hôpital de Sion and Hôpital de Fribourg, Switzerland. Determination
of iron status becomes an important issue in dialysis patients treated
with erythropoietin (EPO). The classically advocated ferritin determi-
nation is not reliable in various conditions (inflammatory states, iron
administration, etc.) and, in addition, even when normal does not
always seem to reflect the available iron during EPO therapy. Other
commonly used non-invasive methods include serum-iron and trans-
ferrin saturation indexes. Recently, the percentage of hypochromic
erythrocytes in peripheral blood and the intra-erythrocytic zinc-proto-
porphyrin (ZPP) determination have been proposed. The respective
value of these methods remains to be established. The aim of this study
was to evaluate those parameters in comparison to EPO dosage in three
hemodialysis centers with different policies of iron administration
(values expressed as medians (mm., max.):
Center
Months
on HD Hct %
EPO
dose/wk
Ferritin
ng/ml
I (N = 70) 36
(1—188)
32
(27—38)
3000
(500—10000)
1150
(32—4400)
H (N = 36)
I!! (N = 38)
33
(2—145)
48ab
(2—168)
32
26—44)
34ab
(25—40)
6800k
600—21000)
8000k
(4000—16000)
296k
37—3113)
321k
(29—1517)
Serum
TF saturation
index %
ZPP
.unol ZPP/
iron % Hypochromic mol heme
16.4 37 1.5 22.5
(6.2—33.8) (20—43) (0—7.1) (3—100)
13 20.8a o.9a 32.5a
(3.8—34) (9—30) (0.1—4) (8—133)
128ab 35ab
(1—82) (4—27) (0.3—26) (8—111)
a Significant difference if compared to Center!
b Significant difference if compared to Center!!
!n conclusion: (a) The inter-center variation of EPO dosage is probably
explained by the different policies of iron administration, EPO dosage
being lower at the expense of higher ferritin levels. (b) A functional iron
deficiency may exist despite normal ferritin levels. (c) Among the
parameters of iron metabolism, ZPP appears in individual cases as a
promising indicator, but additional longitudinal studies are needed.
Insufficient blood levels of vitamin B! and 86 in patients on continuous
ambulatory peritoneal dialysis (CAPD). H. Gantenbein, M. Schmidli, W.
Riesen, Medizinische Klinik B und Institut für klinische Chemie,
Kantonsspital St. Gal/en, Switzerland. In 15 CAPD patients (age 51.9
13.8years, time on CAPD 3.17 2.93years) blood levels of vitamin BI,
82 and B6 were measured using erythrocyte enzyme activities. All
patients were encouraged to eat an unrestricted diet containing more
than one gram of protein/kg/day. All patients showed normal blood
levels of vitamin B2. Vitamin Bl levels were low in six patients,
borderline in three patients and normal in six patients. Vitamin B6
levels were low in 10 patients, borderline in two patients and normal in
three patients. After three months of supplementation with a multivi-
tamin preparation (DreisavitR, one tablet/day), vitamin Bl and B6 levels
were normal in 10 of 11 patients. Four patients didn't finish the study,
two patients refused to eat the tablets because of their bad smell or
nausea, two patients had severe infections. We could not show any
correlation between protein catabolic rate and vitamin status. Age, time
on CAPD and serum albumin showed also no relation to the vitamin
status. In conclusion, in spite of an unrestricted diet, most CAPD
patients show insufficient blood levels of vitamin B 1 and B6. A simple
supplementation with a multivitamin preparation can correct this defi-
ciency.
Hepatitis C virus marker in hemodialysis patients. A. Edward, E.
Walder, S. Crestani, J.A. Cerutti, V. Deiss, M. Senn, J.J. Burckhardt,
Ospedale Civico, Lugano, Central Laboratory SRK Bern, Switzerland.
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The aim of this study was to identify patients (pts) with HCV and the
relationship with any previous history of blood transfusion (TRSF),
duration of the dialysis, and serum aminotransferase (ALT) activity.
Further the seropositivity was re-evaluated one year later following the
introduction of preventive infection measures. The study included 159
ESRD pts, 99 males and 60 females. They were placed into four groups
as follows: Group A, renal transplanted (TP), N = 46; Group B,
maintenance hemodialysis patients (MHD), N = 65; Group C, contin-
uous ambulatory peritoneal dialysis (CAPD), N = 30; Group D,
pre-terminal end-stage renal disease (PTESRD), N = 18. None of the
pts were HIV positive or intravenous drug abusers. Anti-HCV was
determined with both 1st and 2nd generation assays and confirmed by
RIBA-2 blot assays. HCV-RNA was determined after reverse transcrip-
tion using PCR with nested primers located in the fifth non-coding
region. The seroprevalence of HCV marker is markedly higher in the
MHD group (36%) with respect to CAPD (23%) and PTESRD (11%)
groups. HCV marker was positively and frequently associated with
previous TRSF and suggests that HCV infection due to TRSF cannot be
neglected. In group B 15/23 HCV positive were transfused versus 15/42
HCV negatives, in group C 6/7 versus 8/23, in group D 2/2 versus 1/16.
Only a small number of patients who were HCV positive demonstrated
a moderate, transient increase in ALT. HCV viremia with anti-HCV
antibodies was found in 16(27%) and one year later in only 4(6%) of the
patients. This disappearance of the HCV-RNA from the blood may be
associated with recovery from the infection or by an intermittent
serological appearance of the virus. Neither the disappearance of the
anti-HCV antibodies nor an increase in HCV carriers was observed
during the study period. In conclusion, the high incidence of non-
transfusion related HCV seropositivities in MHD suggests the possibil-
ity of cross-infection by an unapparent parenteral transmission of the
virus. The HCV-RNA is the only reliable diagnostic marker of hepatitis
C viremia and its the crucial factor in determining contamination,
although a negative or marginal antibody assay does not exclude the
presence of HCV-RNA in serum.
Urine endothelin In kidney transplant patients, hemodialysis patients
and normal healthy subjects. M. Zeiler, B. Loffler, A. Bock, M.
Spoendlin, G. Thiel, Kantonsspitai Base! Universitätsk!iniken, F. Hoff-
mann-La Roche Ltd., Base!, Switzerland. Whether renal excretion of
endothelin-l (ET-1) in patients with renal failure is increased or
decreased compared to normal healthy subjects is still controversial.
We evaluated this question by comparing ET-l excretion in three
groups with different renal function. Urine ET-I was measured in 18
kidney transplant patients (KTP) on the first day after transplantation,
in 6 hemodialysis patients (HDP) with residual renal function and in 10
normal healthy subjects (NHS). Plasma ET-l was determined only in
the HDP and NHS patients, thus allowing ET-l clearance measure-
ments. KTP and NHS urine collection time was 1 to 3 hours. In HDP
collection time was 24 hours. KTP urine was taken from a catheter
draining the transplanted kidney.
KTP
(N = 18)
HDP(N = 6)
NHS(N = 10)
Urine ET-I pg/mi 66 26 56 13 68 34
Urine flow mI/mm 3.9 5.6 0.7 0.4 1.4 1.1
Urine ET-1 excretion pg/mm 210 281 37 22 75 36
Plasma ET-l pg/mi not done 26.0 2.0 13.4 2.2
El-I clearance mi/mm not done 1.4 0.8 5.5 2,3
Creatinine clearance mi/mm 30 45 2 1 117 35
Urine ET-l per urine 25.9 17.2 19.6 7.4 11.2 4.6
creatinine pg/pmol
Taken as a whole, absolute urinary ET-l excretion did not parallel renal
function. However absolute ET-1 excretion was highest after transplan-
tation and within this population directly dependent on creatinine
clearance (correlation, r = 0.95, P < 0.001). Whether the high excretion
of ET-l in KTP during the first day is due to high plasma ET-1 levels
accumulated during renal failure or an effect of activated renal ET-l
production under the influence of cyclosporin A (CsA) remains to be
determined. The lowest absolute urine ET-l excretion was found in
HDP, the highest in KTP. Fractional El-I excretion was highest in
KTP and also significantly increased in HDP as compared to NHS
(Mann-Whitney, P < 0.02). In conclusion, absolute urinary ET-l
excretion is flow dependent, but fractional excretion is not. The highest
absolute and fractional El-I excretion was found in KTP, which may
be related to CsA therapy.
Is the recovery of plasma creatinine after discontInuation of cyclosporin
A followed by an equivalent recovery of glomerular filtration rate?
Results of a prospective study. M. Zeiler, A. Bock, R. Zflrcher, A.
Gratwohi, G. Thiel, Kantonsspitai Base! Universitätskiiniken, Base!,
Switzerland. In clinical practice plasma creatinine (Pr,,) is used to
estimate changes of glomerular filtration rate (GFR). Generally it is
believed that recovery of Cr within 10% of initial baseline allows to
exclude relevant nephrotoxic changes. We evaluated whether recovery
of GFR after discontinuation of cyclosporin A (CsA) therapy can be
adequately predicted by measuring 1Cr alone. Fifty-four allogenic bone
marrow transplant (BMT) patients were followed up by Cr and
classical inulin clearance (GFR) before BMT (baseline) and 1, 3, 6, 12,
18, 24 months after BMT. A total of 10 patients fulfilled following 3
criteria: (1) 24 months total follow-up time; (2) at least 12 months
follow-up after discontinuation of CsA therapy; (3) no trimethoprim
comedication at time of clearance measurement (interference with
creatinine excretion). The following values for 1Cr, GFR, body weight
and 12-hour creatinine excretion (mean SD) were calculated for
patients fulfilling the above-mentioned criteria.
N = 10 Baseline 24 Months after BMT
PCr .unol/1iter 81 15 80 19
GFR mi/mm 105 30 80 20
Body weight kg 68 12 66 13
12-hr creatinine excretion 6573 1822 6339 1926
pinoi/12 hr
The time after CsA withdrawal varied between 13 and 21 months (mean
5D 17 2 months); the mean duration of CsA therapy was 8 2
months. After at least 12 months of CsA cessation PCr recovered to
baseline values (mean percentual change 0.4 18%, paired sample
i-test, P = 0.94). In contrast GFR remained about 20% below baseline
(mean percentual change —20 22%, paired sample t-test, P < 0.02).
Neither creatinine excretion nor body weight changed significantly
between baseline and 24 months after BMT. In conclusion, follow-up of
1Cr after CsA cessation can overestimate the recovery of GFR. A 20%
loss of GFR may remain unrecognized.
Interleukin-6 exacerbates the glomerulonephritis of (NZBxNZW)F1
mice. B. Ryffel, B.D. Car, H. Gunn, P. Hiestand, Mi. Mihatsch,
Institute of Toxicology, Faculty of Medicine, University of Zurich,
Schwerzenbach/Zurich, Switzerland; Sandoz Pharma Base! and East
Hanover, New Jersey, USA; and Institute of Pathology, University of
Base!, Switzerland. The ability of interleukin-6 to modulate immune
parameters and mesangial cell function suggests a role for this cytokine
in the development of autoimmune glomerulonephritis. This hypothesis
was tested in 6-month-old (NZBxNZW)F1 mice which were adminis-
tered IL-6 (50 and 250 tg/kg s.c.) for 12 weeks, resulting in an
accelerated severe form of membranoproliferative glomerulonephritis
associated with a marked up-regulation of mesangial MHC class II
antigen and glomerular ICAM-1 expression. To distinguish the direct
effects of IL-6 on the renal mesangium from those mediated through
immune system stimulation, mice were immunosuppressed with cyclo-
sporin. This immunosuppression inhibited the development of glomer-
ulonephritis, decreased class II antigen expression and abrogated IL-6
mediated effects. NZW and Balb/c mice given high doses (500 sg/kg) of
IL-6 failed to develop morphologic or biochemical evidence of glomer-
ulonephritis. Induction of acute phase proteins, anemia and thrombo-
cytosis confirmed the biological activity of IL-6 in these mice. IL-6 is
therefore able to accelerate the development of the genetically deter-
mined glomerulonephritis of (NZBxNZW)Fl mice through effects me-
diated by a modulated immune system, but is non-nephritogenic in
normal mice.
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Endothelin-1 does not mediate the hypoxemia-induced renal dysfunc-
tion in newborn rabbits. D.S. Semama, M. Thonney, J.-P. Guignard,
Service de pédiatrie, CHUV, Lausanne, Switzerland. In the newborn
rabbit, acute normocapnic hypoxemia increases the renal vascular
resistance, leading to renal hypoperfusion and decreased glomerular
filtration rate. Because endothelin, a potent vasoconstrictor peptide
produced by vascular endothelial cells, induces a long-lasting vasocon-
striction of both the afferent and the efferent arterioles, we speculated
that it could mediate in part the hypoxemia-induced vasoconstriction.
To test this hypothesis, experiments were performed in 24 anesthetized
and mechanically ventilated newborn rabbits aged 5 to 8 days. Renal
blood flow and glomerular filtration rate were determined by the
clearance of para-aminohippuric acid and inulin, respectively. Each
animal acted as its own control. In eight newborn rabbits (group 1), a
bolus injection of 5 nmol kg of endothelin (human endothelin-1,
Peptides International) caused a marked increase in mean blood pres-
sure and renal vascular resistance, leading to a significant fall in
glomerular filtration rate (—12 4%) and renal blood blow (—16 3%).
A second group of animals (N = 8) confirmed the neutralizing activity
of the endothelin-l antiserum in vivo (endothelin-1 antiserum, Peptides
International). In spite of pretreatment with endothelin-1 antiserum,
hypoxemia induced an increase in renal vascular resistance (+40
18%; P < 0.05) associated with a significant fall in glomerular filtration
rate (—18 7%) and renal blood flow (—29 6%) in eight newborn
rabbits (group 3). The present results suggest that endothelin-1 does not
mediate the hypoxemia-induced renal changes.
Identification of two different isoforms of the Na-K-ATPase along the
rat nephron. E. Féraille, M. Rousselot, C. Bar! et-Bas, A. Doucet, H.
Favre, Hôpital Cantonal Universitaire, Genéve, Switzerland and Col-
lège de France, Paris, France. Ion transport along the nephron depends
on heterogenous mechanisms characteristic of each segments. Renal
tubular cells are polarized, thus allowing ion reabsorption and secre-
tion. Segment specificity of the apical Na transport systems is well
established, whereas Na-K-ATPase is located at the basolateral border
all along the nephron. However, the Na-K-ATPase activity is specifi-
cally controlled in each nephron segment suggesting the expression of
different isoforms of the enzyme. For this purpose, we measured the
ouabain-sensitivity and the inhibitory action of anti-al and anti-a3
antibodies (Ab) on the Na-K-ATPase activity in single segments of rat
nephron. Ouabain inhibition curves demonstrated the presence of two
populations of Na-K-ATPase defined by their ouabain sensitivity. The
apparent K05 of the high-sensitive population was 8.7 10—6 M in
proximal convoluted tubule (PCT); 1.1 10-6 M in medullary thick
ascending limb (MTAL); and 1.4 10-6 M in cortical collecting duct
(CCD) whereas the apparent K of the low-sensitive one were 4.6 lO
M in PCT; 1.8 lO M in MTAL; and 2.6 iO M in CCD. The relative
proportion of high versus low ouabain-sensitive populations was (in %):
PCT 30 vs. 70; MTAL 20 vs. 80; and CCD 45 vs. 55. The proportion of
Na-K-ATPase activity inhibited by the anti-a3 Ab versus the anti-al Ab
was in good agreement with the respective proportions of each isoform
calculated from the ouabain inhibition curves (in %): PCT 26 vs. 46;
MTAL 38 vs. 67; and CCD 50 vs. 64. These results demonstrate: (1)
a3-IR and a! isoforms of the Na-K-ATPase are expressed all along the
rat nephron; (2) the high ouabain-sensitive isoform a3-IR is more
abundant in CCD than in PCT and MTAL, which may be of physiolog-
ical importance as the final regulation of Na excretion takes place in the
collecting duct.
Cuprophan membranes increase phospholipase A2 (PLA2) activity.
C.A. Fux, B. Vishwanath, F.J. Frey, B.M. Frey, Abteilung für Neph-
rologie, Medizinische Universitatspoliklinik, Bern, Switzerland. Hemo-
dialysis in humans and experimental animals may result in some
adverse reactions with anaphylactic patterns, mainly due to the inter-
action of blood with artificial membranes. The frequency of such
adverse reactions depends on the type of membranes used. Several
studies report increased complement activation, leukopenia, an in-
creased synthesis of 5-HETE, l2-HETE, thromboxanes and pros-
taglandins with cuprophan filters. The increased synthesis of thrombox-
anes and prostaglandins indicates enhanced release of arachidonic acid
(AA). AA is mainly released by PLA2. Whether PLA2 is activated by
bioincompatible filters is unknown. Therefore in the present study
PLA2 activity was measured in plasma from 8 patients on chronic
hemodialysis, once treated with a cuprophan capillary dialyzer (Hemo-
flow E4S, Fresenius) and once with a cellulose triacetate hollow fibre
dialyzer (CT11O, Baxter). On each occasion 6 blood samples were
collected just before and during dialysis. To purify the acid and heat
stable form of PLA2 from other, non-inflammation-linked PLA2 and
lipoprotein inhibitors in the plasma, the plasma samples were exposed
to both acid and heat. The activity of the remaining enzyme was
quantified with a bioassay measuring the release of radioactive fatty
acids from E. coli membranes during 2 hours incubation. With both
dialyzers the PLA2 activity increased. The increase was more pro-
nounced with cuprophan than with triacetate dialyzers. The area under
the activity versus time curve was 1713% lysis x mm (SD 436) with
cuprophan and 1035% lysis x mm (SD 472) with triacetate fibres (P <
0.02). There was no significant difference between arterial and venous
blood, leaving uncertain whether the activation takes place in the body
or in the dialyzer, yet underlining the stability of PLA2 activation state.
In conclusion, hemodialysis treatment activates PLA2, the key enzyme
of the inflammatory cascade, and its activation is dependent upon the
material used for the dialyzers.
Cardioeirculatory investigations during hemodialysis combining bio-
impedance with continuous blood volume monitoring. M. Togni, U.
Binswanger, Nephrologische Abteilung, Departement für Innere
Medizin, Universitatsspital Zurich, Switzerland. Eleven patients were
evaluated before, after and during recovery from a normalized ultrafil-
tration pulse of 20 mm duration. Factors counteracting blood volume
contraction include: (1) "refilling" from extravascular compartments
reflected by the capillary filtration coefficient, which showed a wide
spread of 2.2 to 11.0 ml/(min mm Hg . 50kg lean body mass); patients
with the lowest values exhibited large blood volume contraction; (2)
cardiac output as derived from cardiac index measurements was not
changed during the observation period; (3) a decrease in venous
circulation capacity reflected by measurements of preload (due to
increased venous flow during stable cardiac output) was unchanged. (4)
Systemic vascular resistance calculated from cardiac index and sys-
temic pressure showed an increase during ultrafiltration from 2248
882 to 2695 901 dyn sec cm5 m2 (P < 0.001). Refilling and
systemic vascular resistance were found to be of major importance for
volume homeostasis during ultrafiltration. The methods employed are
able to dissect mechanisms involved in hypotension-prone hemodialy-
sis patients.
Evaluation of a new dialyzer-reuse (DR) system. D. Kiss, K. Donauer,
I. RosIer, Dialysestation, Medizinische Klinik, Kantonsspital Liestal,
Switzerland. To optimize the quality of DR, we developed an auto-
mated, self-desinfecting sterile-operating reprocessing system, with
reverse ultrafiltration using bleach wash, peracetic acid and large
amounts of sterile water. Over a 24 month period, the water quality of
the reprocessing system, the elimination of the desinfectant and the
dialyzer permeability in 10 chronic hemodialysis patients was investi-
gated. The quality of water used for DR was determined by measuring
the bacterial content with full-stream samples (Millipore 0.45 nm) in the
water pathway, and the endotoxin concentration by a colorimetric
assay (Coatest). The quality of the desinfectant washout was deter-
mined by the peroxide concentration (Peroxid-Test) in the rinsing water
before reuse. The dialyzer permeability was determined by measuring
the ultrafiltration coefficient at the beginning and at the end of treatment
and the low molecular clearance (urea and creatinine) was determined
by collecting the dialysate during treatment in 10 patients (1 to lOx
reuse). Data are expressed as mean SD. In contrast to the reverse
osmosis water used for the reprocessing system, all full-stream samples
showed no bacterial growth. The endotoxin concentration of the
reverse osmosis water was 5.28 1.19 pg/mi and of the DR-system 4.23
0.48 pg/mI. The peroxide concentration after rinsing with the DR
System was always below 0.3 mg/liter. The ultrafiltration coefficient at
the beginning and the end of treatment did not change from the 1st to
the 10th reuse (19.9 1.4 vs. 20.0 1,2 mI/hr mm Hg and 17.2 1.4
vs. 17.0 1.2 nil/hr mm Hg). Creatinine clearance was 139 11 mI/mm
during the 1st use and 139 7 mI/mm after the 10th reuse. Urea
clearance was 182 10 mI/mm during the 1st use and did not change
during 10 reuses (185 9 mI/mm). During the 24 month period no side
effects could be observed in the patients treated with reused dialyzers.
The reverse ultrafiltration system for DR excludes a possible contami-
nation between patients. The self-desinfecting DR system is sterile in
operation and the efficiency of desinfectant elimination results in its
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complete removal. The dialyzer permeability during 1 to 10 reuses
remained unchanged. Since dialyzer quality remains constant, repro-
cessing is performed under sterile conditions and desinfectant is re-
moved completely, contamination between patients is excluded by
reverse ultrafiltration and no adverse effect on survival can be antici-
pated when DR is correctly performed.
Risk and benefits of percutaneous renal biopsy (PRBx): A comparison
of two techniques. D. Kiss, K. Donauer, W. Wegmann, Nephrologie,
Medizinische Klinik und Institut für Pathologie, Kantonsspital Liestal,
Switzerland. The adequacy of tissue for diagnosis (ATD) and safety of
ultrasound guided PRBx using the 14 gauge (G) "Trucut" needle (TCN;
N = 60)was compared with PRBx using the 180 spring loaded vacuum
needle "Autovac" (AVN; N = 53). All PRBx (N = 113) performed
between 1988 and 1993 at one center were evaluated retrospectively.
ATD, the number of glomeruli and the length of specimens were
determined. Safety assessments were based on the incidence of post-
PRBx complications: gross hematuria, local pain, fall of hemoglobin(Hb) concentration, the need for transfusions and other clinically
relevant complications. Groups were comparable for age, renal size,
blood pressure, coagulation parameters and renal function. Data are
expressed as mean s.
TCN (N = 60) AVN (N = 53)
ATD
Length of specimen mm
Number of glomeruli
Minor complications
Fall of Hb g%
Fall of Hb > 2 g%
60(100%)
14.5 7.7
12.5 6.6
18 (30%)
0.92 0.78
5 (6.2%)
53 (100%)
34.0 l5.3
11.1 6.4
9 (l7%)
0.65 0.47a
oa
a P < 0.05
We conclude that the yield of biopsy material which was sufficient for
diagnosis was equivalent with both techniques. The 180 AVN delivers
longer specimens with the same amount of glomeruli, Due to its smaller
gauge, the AVN caused significantly fewer complications in comparison
with the TCN. Hence the 18 G AVN lowers the morbidity of PRBx and
could be suitable ambulatory procedures.
Mortality and hypotensive episodes with short-time high-flux dialysis
(HFD). D.E. Uehlinger, M. Keen, F.A. Gotch. Abteilung für Nephrol-
ogie, Medizinische Poliklinik der Universität Bern, Switzerland and
Davies Medical Center (DMC), San Francisco, California, USA. We
analyzed all our patients (N = 103) who had their treatment initialized
as HFD over an observation period of 4 years. All patients were
controlled by monthly urea kinetic modeling (UKM) and had a pre-
scribed KT/V (V calculated from surface area) of 1.06 and observed
KT/V (V calculated by UKM) from 0.9 to 2.2. Mean treatment time was
2.25 hours. Mean age was 62 years (56% were older than 65 years) and
prevalence of diabetes (DM) was 22%. The overall annual mortality rate
(MR) in our patients was 14%/year. MRs calculated from EDTA and US
HCFA data for patients matched to the same age and DM distribution
were 17 and 26%/year, respectively. Significant covariates of survival in
our patients were normalized protein catabolic rate (NPCR) (P <
0.003), BUN (P < 0.002), creatinine (P < 0.001) and albumin (P <
0.001). Multivariate analysis revealed low NPCR and low creatinine as
predictors of mortality (P < 0.001). Analysis of prescription and
observation parameters revealed only ultrafiltration rate as a predictor
of hypotensive episodes during hemodialysis (P < 0.001; ANOVA).
Nevertheless, a higher proportion of patients with any reported hypo-
tensive episode had a NPCR> 1.2 g/kglday (P < 0.04), a phosphorus>
6 mg/dl (P < 0.001), a treatment time > 2 hours (P < 0.02), a blood flow
<350 mI/mm (P < 0.04) and was dialyzed 3 vs. 2 times per week (P <
0.01; cross table analysis, weighted by individual/mean number of
hypotensive episodes). In conclusion, HFD does not increase the
mortality rate in our population and hypotensive episodes are not
directly related to short time HFD.
Estimation of daily protein-excretion without exact 24-hr urine volume.
Y. Schoch Zysset, M. Zeiler, A. Bock, G. Thie!, Division Nephrology,
Dept. Internal Medicine, Kantonsspital, University of Base!, Switzer-
land. Quantitative measurements of daily protein excretion in the urine
(UP/day) depend on exact 24-hr urinary volume measurement (24hr-U-
Vol), a source of mistake. It would be helpful if UP/day could be
estimated accurately from the quotient of urinary protein and urinary
creatinine concentration (P/Cr) without knowledge of 24hr-U-Vol. To
evaluate how much quantitative information concerning UP/d can be
gained from urinary P/Cr measurement alone, we used the following
formulas, which are based on 4 parameters [(1) age, (2) weight, (3) sex,
(4) and P/Cr]: UP/day = P/Cr x eA — Cr/day. eA — Cr/day = estimated
amount of excreted creatinine/day (mol/day) 1.44 x body weight X
(150 — age) x sex factor (SF). SF for males = 1.1, for females = 0.9,
using the Dettly-Cockroft formula. We analyzed 354 urine samples
collected during 24 hours from 115 renal transplant recipients and
compared the measured UP/day (classical method) with the estimated
UP/day using the described formulas. Results:
Range of Mean SD Mean SD
estimated of estimated of measured
proteinuria Number of proteinuria proteinuria
mg/24 hr samples (mm—max) (mm—max)
<250 197 137 64
(—249)
145 65
(—308)
251—500 71 359 77
(252—499)
340 78
(204—578)
500—1000 40 670 133
(503—994)
650 171
(406—1052)
1001—2000 17 1440 272
(1047—1835)
1323 258
(869—1795)
2001-4000 12 2872 636
(2051—3839)
2918 881
(1544—4452)
4001—8000 5 4922 928
(4038—6403)
5306 1690
(3618—7884)
>8000 1 [10,169] [78%]
In conclusion, urinary protein excretion can be estimated quite accu-
rately without knowledge of 24-hour urinary volume. Whether a spot
morning urine serves as well for this purpose as an aliquot taken out of
a 24 hour collection remains to be shown.
Hyperphosphatemia more than hypercalcemia limits intravenous cat-
citriol therapy in secondary hyperparathyroidism. E. Descombes, G.
Vogel, J. Rosman, J.-P. Wauters, Division de Néphrologie, CHUV,
Lausanne, Switzerland. Intravenous (i.v.) calcitriol has been proposed
as an effective therapy of severe hyperparathyroidism in dialysis
patients. During a 20 week period we studied 8 patients on chronic
hemodialysis with severe hyperparathyroidism (intact-PTH > 3 times
normal values) that did not respond to therapy with calcium-based
binders and oral vitamin D (dihydrotachysterol or calcitriol p.o.). They
were dialyzed from 10 to 79 months (mean = 40 26) with a
bicarbonate dialysate containing 1.75 mmol/liter of calcium (Ca); phos-
phate (P) levels were well controlled with calcium-based binders only
and the phosphate content of the prescribed diet (<1000 mg/day) was
unchanged during the study period. The initial i.v. calcitriol dose was 1
g after each dialysis session and was increased to 2 g in 3 patients at
week 10, Ca and P levels were monitored weekly. After 10 weeks two
patients dropped out due to repeated hypercalcemia (1) and cardiovas.
cular death (1). The main findings of our study were: (a) i.v. calcitriol
effectively improved severe hyperparathyroidism in 6/8 patients on a 20
week period, with a decrease of the intact-PTH in the 6 responders from
567 339 to 231 199 pg/mI (P < 0.05); (b) hypercalcemia (>2.7
mmol/liter) occurred in only 3 patients and was observed in only 12% of
the weekly laboratory controls; most of the hypercalcemic episodes
occurred in one patient having borderline-high Ca levels before the
study and who had to drop out; (c) in contrast hyperphosphatemia (2
mmol/liter) was observed in 7/8 patients and in 35% of the weekly
laboratory controls; in 13% of the cases P values even exceeded 2.4
mmol/liter; the phosphate binder therapy had to be intensified accord-
ingly not only by increasing the dose of calcium-based binders but also
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by introducing aluminum salts in 6/8 patients; (d) no univocal pattern
was found for the evolution of the alkaline phosphatase values that
decreased in 5/6 of the responders from 188 98 to 136 54 lU/liter.
In conclusion, i.v. calcitriol is effective in the treatment of severe
hyperparathyroidism in most hemodialysis patients resistant to oral
therapy; however, its usefulness is limited by the frequency and
severity of hyperphosphatemia necessitating the additional prescription
of aluminum-based binders. Therefore the use of i.v. calcitriol needs
considerable cautions not only for hypercalcemia but principally for
hyperphosphatemic episodes.
Progression of renal failure in insulin dependent diabetics (IDDM).
A. Colombi, H. Wittke, M. Schmid, Renal Unit, Med. Department,
Kantonsspital Luzern, Switzerland. According to several authors,
unfavorable results in the treatment of IDDM patients with end-stage
renal disease favor earlier renal replacement therapy, when creatinine
clearance of about 12.5 mI/mm. Better results are expected in patients
receiving a kidney and pancreas graft at this time with short or no prior
dialysis treatment. We have analyzed a group of 20 patients (12 male
and 8 female) with a mean age of 36.4 7.6 years in order to determine
the progression during preterminal renal failure. We have calculated, on
the basis of the reciprocals of the serum creatinine concentrations, the
time elapsed for serum creatinine values to increase from 250 to 720
mol/liter. This time amounted to 11.8 7.6 (1 to 28) months, and
progression in terms of creatinine clearance loss was 1.74 mI/mini
month, clearly more than was expected. Progression was not signifi-
cantly different in men and women, and there was no correlation
between progression and mean arterial blood pressure. However, there
was a weak correlation between progression and proteinuria, a protein-
uria < 5 g/24 hr being associated with a delay of> 10 months. Mean
proteinuria was 7.41 4.3 g124 hr. Since the interval between work-up
for transplantation and the actual operation was 11.8 7.6 months, it
seems reasonable to enlist the patients for transplantation at a serum
creatinine of 250 mo1 in order to avoid or shorten dialysis treatment.
Dimercaptosuccinic acid scan and ultrasonography to detect renal
lesions in children with pyelonephritis. D. Benador, N. Benador, D.O.
Slosman, D. Nusslé, B. Mermillod, E. Girardin, Département de
Pédiatrie, Hôpital Cantonal Universitaire, Genève, Switzerland. We
designed a prospective study to evaluate the ability of dimercaptosuc-
cinic acid (DMSA) scan and ultrasonography (US) to detect renal
parenchymal changes in children with suspected pyelonephritis. The
study included 111 patients aged I week to 16 years (median 5.5
months) with positive urine culture. DMSA scan and US were repeated
in 25 children after a mean follow-up of 10.5 months. DMSA scan
showed renal changes in 74 children (67%) and US in 39 (35%) (P <
0.001). The 2 exams were discordant in 49 patients (Kappa =0.19).
Children over one year had a higher incidence of renal lesions compared
to younger children (85% vs. 66%, P = 0.04). The presence of
inflammatory signs (ESR or CRP) had an 89% sensitivity and 25%
specificity in diagnosing renal lesions. Among children with renal
changes, vesicoureteric reflux was present in 39%. At follow-up exam-
ination, 16 children (64%) had scars. Twelve of them had VUR and 7 a
history of multiple urinary tract infection. In this study we found a high
incidence of renal involvement in children with suspected pyelonephri-
tis. DMSA scan was more sensitive than US to detect renal changes.
Therefore, when performed in the initial work-up, DMSA scan can
improve the detection of children at risk of developing renal scarring.
Urolithiasis in children living in Armenia. A. Sarkissian, A. Babloyan,
Z. Khachikian, G. Azatian, E. Leumann, N. Blau, R. Asper, Children's
Uro-Nephrological and Surgical Centre, Yerevan, Armenia, Univ.-
Kinderklinik und Institut für Klinische Chemie, Univ -Spital, Zurich,
Switzerland. Urolithiasis is quite common in Armenian children, but
has not been studied by modern methods. Calculi of 49 patients (age <
15 years) obtalned between 1990 and 1993 were examined by X-ray
diffraction. Thirty-one of the 49 patients (63%) were male. There was an
even age distribution with a clear male preponderance (72%) below the
age of 10 years. The prevailing constituent was calcium-oxalate (CaOx)
alone (N = 29) or in combination with apatite, uric acid or ammonium
hydrogen urate (11). Other constituents were struvite (4), uric acid (2),
ammonium hydrogen urate (2) and cystin (1). Twenty-two urines of the
40 patients with CaOx stones were examined: There was a slight
increase of the molar calcium/creatinine ratio (1.06 to 1.47, normal <
0.6) and of the oxalate/creatinine ratio (0.097 to 0.128, normal <0.08) in
3 patients each. In conclusion, contrary to expectations, infectious
stones were infrequent as compared to CaOx stones, for which children
residing in Armenia seem to be prone. In contrast to Armenia, stones
containing uric acid and ammonium hydrogen urate are rarely seen in
children living in Western Europe.
Mixed cryoglobulinemia: Reversibility of acute renal failure with
interferon a2a monotherapy. M. Vonlanthen, P. Guibent M. Levy, J.
Schifferli, Hôpital de Ia Tour Meyrin et Hôpital cantonal universitaire
Genève, Switzerland. A 48-year-old man was found to be a carrier of a
mixed cryoglobulinemia IgG kappa-lambda and 1gM kappa. CH5O, C3
and C4 were low; the latex test was positive; antibodies to C hepatitis
virus were present. He had a twelve year history of purpura, fever,
arthralgias, myalgias, intestinal bleeding, glomerulonephritis, nephrotic
syndrome, and renal failure. At the times of serious clinical exacerba-
tions, he was treated with prednisone, cyclosphosphamide and plas-
mapheresis, whose clinical and biological effectiveness diminished with
time. A relapse occurred in April 1990, with a renal involvement
marked by macrohematuria and a serum creatinine increase from 142 to
270 smol/liter. Interferon a2a monotherapy was started, and there was
rapid clinical improvement, progressive renal function recovering (crc-
atinine 119 mol/liter), disappearance of the cryoglobulin, and normal-
ization of the complement, rheumatoid factor, transaminases and
hemoglobin. Antibodies to C hepatitis remained high, HCV RNA was
negative. This treatment, now 2.5 M units every ten days, allowed more
than 3 years of full clinical and serological remission. The established
relationship between cryoglobulinemia type II and hepatitis C virus is
the rational argument for the use of interferon, which is effective to date
in about 50% of our cases. Considering its low toxicity, interferon
should be used as first treatment in mixed cryoglobulinemia.
Pneumocystis carinii pneumonia during immunosuppressive therapy
of ANCA-positive extracapillary proliferative glomerulonephritls. U.
Huynh Do, H. Gantenbein, U. Binswanger, Nephrologische Abteilung,
Departement für Innere Medizin, Universitãtsspital Zurich, Zurich,
Switzerland. Pneumocystis carinii causes life-threatening pneumonitis
(PCP) in immunocompromized individuals. In a HIV-negative popula-
tion, PCP is frequently associated with corticosteroid therapy, and the
rodent model uses corticosteroid-induced immunosuppression to pro-
voke PCP. Although patients with systemic vasculitis are often treated
with long courses of high-dose steroids, there have been very few
reports of PCP in this population. From August 1, 1991, to August 1,
1993, we diagnosed PCP in 2 patients with ANCA-positive extracapil-
lary proliferative glomerulonephritis undergoing steroid taper. At the
time of diagnosis of PCP, both had been receiving a daily prednisone
dose over 25 mg for more than 4 weeks. Both were cured with high-dose
Trimethoprim/Sulfamethoxazole, and renal function remained stable
under prednisone and cyclophosphamide. Because the prevalence of
PCP has markedly increased during the last few years, PCP prophylaxis
should be considered in patients with vasculitis receiving long-term,
high-dose steroids.
Simultaneous occurrence and remission of bronchiolitis obliterans/
organizing pneumonia (BOOP) with the nephrotic syndrome (minimal
change glomerulopathy). M.-J. Serna, S. Dudli, M. Schmidli, R. Krapf,
Kantonsspital, St. Gallen, Switzerland. Bronchiolitis obliterans/orga-
nizing pneumonia and minimal change glomerulopathy are both cryp-
togenic and, in adults, rare diseases. We report the simultaneous
occurrence and remission of these entities in a 66-year-old male patient
presenting with a "pulmorenal syndrome." The patient was admitted
with a 6 day history of leg edema and gain in weight (5 kilogramms). He
was afebrile and had no pulmonary symptoms. A chest x-ray and
24-hour protein excretion one week prior to occurrence of symptoms
had been normal. On admission, the patient exhibited extensive,
bilateral alveolar infiltrates in both upper lobes and was diagnosed with
the nephrotic syndrome and normal renal function (24-hr urine protein
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excretion rate 9.9 g; plasma albumin 18.7 g/liter). Extensive investiga-
tions for autoimmune and infectious diseases were negative with the
exception of a slightly elevated rheumatoid factor. The open lung
biopsy showed a chronic organizing pneumonia consistent with BOOP.
The renal biopsy showed fusion of podocyte foot processes compatible
with minimal change glomerulopathy, although on electron microscopy
an isolated subepithelial hump was noted. Immunofluorescence studies
were negative, Treatment with prednisone (initially 1 mg/kg body wt,
tapered over 5 months) induced sustained regression of pulmonary
infiltrates and full remission of the nephrotic syndrome after 10 weeks.
The simultaneous occurrence and remission of BOOP and minimal
change glomerulopathy suggest a pathogenetic association of these rare
diseases. However, the nature of this possible link is unclear, and the
response to steroids is no proof for such an association since both
entities are steroid-sensitive diseases.
Characterization of MHC class II antigen-positive cells In rodent
kidney. M. Le Hir, B. Kaissling, B. Car, B. Ryffel, Institut für
Toxikologie und Institut für Anatomie, Zurich, Switzerland. Dendritic
cells occupy a specific position among bone marrow-derived antigen-
presenting cells. Only dendritic cells are able, after migration to lymph
nodes, to elicit a primary immune response by presenting antigens to
and initiating the proliferation of naive lymphocytes. Claims by several
authors of the presence of dendritic cells in the kidney have been
grounded solely on the observation of elongated MHC class II antigen-
positive (MHC 11+) cells. Other authors, however, considered these
features characteristic of macrophages. We attempted to characterize
the MHC 11+ cells in the kidneys of mice and rats by immunocyto-
chemistry at the light- and electron microscopical levels. Their inci-
dence was high in the peritubular interstitium of the outer medulla and
of the cortex and very low in the papilla as well as in glomeruli. In
contrast, the ED2 antibody, considered specific for macrophages in rat,
labeled a cell population occurring mainly in perivascular connective
tissue. The MHC 11+ cells showed distinctive ultrastructural features
as compared with macrophages. In particular their lysosomal apparatus
was poorly developed. Their cytoplasmic processes were intermingled
with those of fibroblasts. The availability of interferon 'y (IFN7)
receptor-negative (knock out) mice provided an additional tool for
discriminating between dendritic cells and macrophages. Indeed it
seems now established that the expression of MHC II in dendritic cells
is constitutively high, while it is dependent on IFNy in macrophages.
We compared the expression of MHC II in negative and in wild type
mice. No differences were observed in the kidney. In contrast in the
liver, sinusoidal cells with the typical distribution and shape of macro-
phages (Kupifer cells) expressed MHC II in the wild type but not in the
negative mice. In conclusion, the MHC 11+ cells in rodent kidneys
show in comparison with macrophages distinctive features in their
distribution and in their ultrastructure and, most importantly, they do
not require IFNy for a strong MHC II expression. They are likely to
represent dendritic cells.
Renal transplantation without any inununosuppresslon two years after
bone marrow transplantation from the same lILA-identical donor. V.
Antonioli, B. Chapuis, Cl. HeIg, J.-F. Bolle, J.-M. Tiercy, M. Leski,
Départements de Médecine et de Chirurgie, Hôpital Cantonal Univer-
sitaire de Genève, Switzerland. Bone marrow transplantation (BMT) as
well as its preparative regimens can give rise to renal complications, in
particular the hemolytic uremic syndrome (HUS), sometimes resulting
in end-stage renal failure. For BMT to be successful (2 criteria: take of
graft and the absence of relapse of leukemia after 2 years), theoretically
an organ of the marrow donor has to be recognised as "self."
Consequently, renal transplantation without any immunosuppression isjustifiable in such cases after ascertaining the "tolerance" of the
recipient with full thickness skin graft. We report the case of a
25-year-old female patient who received an allogeneic BMT from her
HLA-compatible brother. She was in the second complete remission for
acute lymphatic leukemia at the time of grafting. The preparative
regimen consisted of chemotherapy using cytarabine and cyclophos-
phamide as well as total-body irradiation with 6 x 200 cGy. Four
months after the BMT, she developed a HUS which despite aggressive
management associating plasmapheresis with immunoglobulins, aspi-
rim, vincristin and prostaglandins, which resulted in end-stage renal
failure necessitating chronic hemodialysis one month later. Two years
after BMT and after demonstrating the absence of immunocompetent
cells in the recipient by DNA amplification and mimsatellite (complete
chimerism) and the absence of rejection after 6 weeks of a full thickness
skin graft, as well as the absence of hematological relapse, a renal
transplantation was carried out without any immunosuppression. The
evolution after one year is good, without rejection (serum creatinine Ill
mol/liter). We could only find two similar cases in the literature.
Circadian blood pressure (BP) rhythm and indications for ambulatory
24-hour BP (ABP) monitoring after kidney transplantation (KT). M.
Spoendlin, A. Bock, M. Zeiler, G. Thiel, Division of Nephrology,
KantonsspitalBasel, Switzerland. In ESRD, normal BP drop during the
night is often missed. We evaluated if this drop reappears after KT and
on which factors it depends. Furthermore, we examined the impact of
ABP monitoring after KT. In 25 mostly hypertensive CsA-treated
patients ABP was measured with the CH-Druck device 10 2.5 and 24
2.6 weeks after KT. Eighteen patients completed a third measure-
ment after 1 year, and in 16 a fourth was done on day 12 1.3 after KT.
The degree of BP drop during the night and the influence of prednisone,
CsA dose, function of transplant, anemia, body mass index, antihyper-
tensive therapy, duration of dialysis and cardiac neuropathy (Pro-
SciCard computer) on the BP drop was evaluated. Further office BP
(OFBP) minus ABP was determined. In addition 3 subjects after donor
nephrectomy (Nx) and 8 controls were investigated. Results: (mean and
SCM, P value: controls vs. patients at different times after KT)
weeks after KT —+ 1—2 10 24
% mean nocturnal BP drop 2.6 1.3 3.1 1.1 2.3 1.6
52 After donor Nx Controls
5.3 1.8 16.3 16 2.0 (P < 0.015)
No correlation between the above-mentioned factors and the degree of
BP drop 10 and 24 weeks after KT was evident from multivariate
regression. Steroids were often stopped between weeks 10 and 24. CsA
was always continued.
weeks after KT — 10
ABP day night
syst. OFBP minus ABP 4.0 1.9 9.1 2.6
diast. OFBP minus ABP —1.0 1.3 4.2 1.6
24 EH
day night day night
4.1 2.8 9.4 3.1 14.2 30.2
—3.6 1.5 2.12 2.0 6.7 19.7
a Patients with essential hypertension from the literature
At 10 and 24 weeks after KT, 29% respectively, 35% of patients with
diastolic OFBP <90mm Hg had diastolic daytime ABP >90mm Hg. In
contrast to EH and normotensive controls, the physiological nocturnal
BP drop after KT was often missed or even inverse up to 1 year.
Multiple regression did not identify a causal relationship between any of
the factors mentioned above and the absence of a BP drop until 24
weeks after KT. CsA cannot be excluded as a responsible factor
because it was never stopped. Having only one functioning kidney does
not disturb the circadian BP rhythm as shown in subjects after donor
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nephrectomy. Furthermore, the increase in BP during office measure-
ments ("white coat effect"), as usually seen in normotensive controls
and EH, was weak or lacking after KT. After KT OFBP and 24 hour
ABP were closer than in EH (less "white coat effect" and less
nocturnal BP drop), so that for any elevated or borderline OFBP value,
the cardiovascular risk, which is associated with ABP (24 hr BP load),
is on average higher than in EH. In conclusion, after KT patients with
borderline OFBP should be evaluated by ABP measurement since
OFBP underestimates the effective 24 hour BP load in contrast to
patients with EH. If borderline BP is maintained over 24 hours, we
suggest starting or intensifying antihypertensive treatment.
Long-term benefits and risks of cyclosporin A therapy: An analysis at
ten years. G. Thie!, A. Bock, M. Spondlin, F.P. Brunner, M. Mihatsch,
J. Landmann, Departement Innere Medizin, Chirurgie und Pat hologie,
Universigät Base!, Switzerland. To evaluate long-term benefits and risks
of cyclosporin A (CsA) therapy in renal transplantation, we analyzed
the ten year experience with all 59 patients who had received a first
cadaveric renal graft by August 1983 and were immunosuppressed with
CsA. We compared their actual graft survival with that of all 213
patients, who had received a first cadaveric graft from 1967 until August
1983, but were immunosuppressed initially with azathioprine and pred-
nisone (AzaP). For comparison of p-creatinine, proteinuria, blood
pressure, lipids, uric acid and skin malignancies, we evaluated the
patients staying unchanged on initial therapy for ten years (CsA = 12,
AzaP = 53). (1) Actual graft survival at ten years was 34% (20/59) with
CsA and 27% (58/213) in AzaP treated patients (intention to treat) (P =
0.09 = NS). At 1 to 5 years graft survival, graft survival was 15%
superior with CsA, but after seven years the survival curve of the CsA
group closely joined the chronic decline seen in the AzaP group. This
behavior could neither be explained by chronic CsA nephrotoxicity nor
by chronic rejection after switching from CsA to AzaP. (2) P-creatinine
at ten years was significantly (P < 0.03), but mildly elevated under CsA
(130 52; AzaP = 109 65). (3) Proteinuria (g/day) at ten years was not
significantly different (CsA = 0.41 0.58, vs. AzaP = 0.83 1.61). (4)
Systolic blood pressure was higher at ten years under CsA (152 19)
than under AzaP (136 23) (P < 0.02), but diastolic pressure was not
(89 10 vs. 84 12, NS). Antihypertensive drug/patient was twice as
high under CsA (1.25 vs. 0.64, P < 0.02). (5) Cholesterol, triglyceride,
HDL were not different. 75% of the CsA patients were steroid free at
ten years, whereas none of the AzaP patients were steroid free. (6)
P-uric acid was not significantly different in both groups (494 192 vs.
400 124), but 42% of CsA patients were on a uric acid lowering drug
(given after at least one gout attack) as compared to 9% under AzaP (P
<0.006). (7) 17% of patients under CsA for ten years had at least one
skin cancer, which was not different from 15% of AzaP patients. In
conclusion, the main benefit of CsA was the better graft survival of up
to five years and the chance to stay free of steroids. The main risks of CsA
were nephi-otoxicity, hypertension and symptomatic hyperuricemia. No
differences were found for hyperlipidemia and skin malignancies.
Hyperuricemia in cyclosporin A (CsA)-treated patients: A GFR-re-
lated, not a CsA-specific effect. R.M. Zürcher, H.A. Bock, G. Thiel,
Abteilung für Nephrologie, Departement Innere Medizin, Kantonsspi-
Ia! Base!, Base!, Switzerland. To investigate the pathogenesis of
CsA-associated hyperuricemia, we prospectively studied bone-marrow
transplant patients (BMT) (N = 29; before, 6, 12, 18, 24 months after
transplantation) and renal transplant patients (RTP) (N = 32; one year
after transplantation) under CsA, and—as a control group without CsA
and comparable renal function—living-related kidney donors (LRKD)(N = 28; before and one year after unilateral nephrectomy). Inulin
clearances by classical clearance techniques were performed and the
fractional clearance of uric acid (fCUA; %) was calculated. GFR ranged
from 17 to 170 mllmin. In BMT, the fCUA remained unchanged before
(14.3 1.2) vs. during (15.3 2.3) vs. after (12.8 1.2) CsA treatment,
whereas GFR changed significantly (106 6 vs. 51 6 vs. 79 5
mi/mm). The fCUA was identical in LRKD (11.1 0.8), RTP on (11.9
0.9) and in BMT on (15,3 2.3) or off (12.8 1.2) CsA, while GFR
was comparable in the different groups. In paired tests, fCUA was 10.9
0.8 in LRKD and 10.3 0.7 in RTP, 13.0 1.6 in BMT before and
13.3 0.9 in BMT under CsA. Plasma uric acid (PUA) rose significantly
during CsA therapy in BMT and decreased to normal levels after CsA
was stopped. Their levels of PUA were comparable to those of RTP. In
conclusion, there is no difference in the fCUA between patients under
CsA and controls with comparable renal function and no immunosup-
pressive drug. Intraindividually, the fCUA remains unchanged before,
during and after CsA therapy. The two kidneys of one donor, one
subject to CsA (RTP) and the other not (LRKD), have the same fCUA.
Therefore, the hyperuricemia observed in CsA-treated patients is due to
CsA-related diminished GFR and not to a specific, CsA induced
tubulotoxic effect. Paralleling the improvement of GFR after CsA
withdrawal, hyperuricemia is reversible.
Vocational rehabilitation in young ESRD patients treated with highly
efficient dialysis. B. von Albertini, George Washington University,
Washington, D.C., USA. The ultimate goal of any renal replacement
therapy for ESRD is to minimize patients' illness and restore them to a
functional life. If clinical outcome of the therapy is measured by the
patients' vocational rehabilitation rates, results are generally far from
satisfactory and have changed little over the last two decades. With the
possible exception of renal transplantation and to a lesser degree with
CAPD, only a minority of patients on maintenance hemodialysis are
working. Contributing factors for this outcome are the absence of
well-being with inadequate therapy and the time involved with the
treatments. Vocational rehabilitation rates were measured in a dialysis
unit dedicated to provide highly efficient hemodialysis with short
treatment times. For this purpose, the survey was limited to the
hemodialysis population aged 18 to 55 with  1 year on the therapy. The
study population (means SD) was 45 ESRD patients with residual
GFR < I mI/mm, Sex: 31 Male, 14 Female, Race: 36 Black, 9 White,
Age 44 8 years, Duration of ESRD 5.4 5.0 (range 1 to 21) years
(etiology: hypertension 29%, diabetes 16%, GN 13%, HIV 9%, PCKD
7%, other or unknown 26%), weight 72 17 kg. The patients were
treated with 4 different therapies (% of total): (1) conventional hemo-
dialysis (7%): Cuprophan 1.1 m2, Q (nominal) 300 mI/mm; (2) high-
efficiency hemodialysis (9%): Cuprophan 1.6 m2, QB 500; (3) high-flux
hemodialysis (31%): Polysulfone 1.8 m2, Q 488 32; (4) high-flux
hemodiafiltration (53%): Polysulfone 2 x 1.8 m2 in series, QB 618 55,
volume of substitution (by backfiltration of in-line filtered dialysate) 24
3 liter/treatment. All treatments were done with bicarbonate dialy-
sate; the access needles used were 15 gauge and 14 gauge. Automated
reprocessing for dialyzer reuse with 4% formaldehyde was practiced in
84% of the patients. Adequacy of delivered therapy was measured by
urea kinetic analysis, with post-treatment samples obtained 15 mm after
the end of treatment. Mean weight loss was 3.3 1.3 kg/treatment.
Mean thrice weekly treatment time was 177 30 mm. Mean delivered
Kt/V by this method was 1.35 .34. Due to physical impairment, 7
(16%) patients were unable to work. Of those able to work, 5 (11%)
chose not to work (includes housewives), 2 (4%) were unemployed, 2
(4%) worked part-time and 29 (64%) worked full-time (gainfully em-
ployed or attending school). Rehabilitation rate (No. working/No. able
to work) was 0.82. In conclusion, high work and vocational rehabilita-
tion rates were observed in this unselected group of young ESRD
patients treated with highly efficient dialysis. It is suggested that among
other factors, adequate quantity of delivered therapy and more time
available outside of dialysis may have contributed to the high function-
ality of these patients.
Intravenous la-OH-I)3 in the treatment of severe secondary hyperpar-
athyroidism. M.J. Oeh,y, G. Thie!, F.P. Brunner, Departement für
Innere Medizin, Universitätsk!iniken, Kantonsspital Base!, Switzer-
land. Control of severe secondary hyperparathyroidism in dialysis
patients may be effected by high dose intravenous l-25-OH-D3 more
promptly and with less hypercalcemia than by oral treatment. A similar
efficacy regarding suppression of hyperparathyroidism has been re-
ported for intravenous la-OH-D3. This drug was, therefore, adminis-
tered to a series of 11 patients with severe progressive secondary
hyperparathyroidism, who were unresponsive to continuous low dose
oral l-25-OH-D3 or refused parathyroidectomy despite hypercalcemia.
For the first 6 patients a dose of 1 zg 1 a-OH-D3 after each dialysis (3 g
per week) was chosen. Although a decrease in plasma 1-84 PTH was
obtained in 2 of these 6 patients, the dosage was increased to 2 tg after
each dialysis in 4 patients and to 4 g 3 times a week in 1 patient. All the
others received 2 g boluses. Before treatment, all except 1 (plasma Ca
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2.55 mmol/liter) had mild hypercalcemia (2.74—3.00 mmotfliter) and 1-84
PTH between 297 ng/liter to 682 ng/liter. The effect of long-term i.v.
la-OH-D3 on PTH levels could be evaluated in 8 patients. 1-84 FF11
decreased in 5 and remained unchanged or increased in 3 patients. In 3
of the 5 responsive patients, la-OH-D3 had to be discontinued after 9 to
12 months because of worsening hypercalcemia. In a further 2 patients
treatment with 1-a-OH-D3, though uneventful, could not be evaluated
because they died of unrelated causes. In one patient la-OH-D3 had to
be discontinued after a few weeks because of generalized itching
appearing within 1 hour of each injection (allergic reaction to propy-
lenglycol ?). In conclusion, bolus injection of la-OH-D3 in a dose of 2
to 4 g thrice weekly may control progressive secondary hyperparathy-
roidismus in some patients who are unresponsive to low-dose oral
calcitriol and mild hypercalcemia.
